TCM Biotech International Corp. (TPEX:4169)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
56.30
+0.30 (0.54%)
Apr 2, 2025, 1:31 PM CST
6.43%
Market Cap 3.35B
Revenue (ttm) 834.32M
Net Income (ttm) 20.00M
Shares Out 59.05M
EPS (ttm) 0.34
PE Ratio 164.47
Forward PE 41.69
Dividend 0.29 (0.50%)
Ex-Dividend Date n/a
Volume 18,898
Average Volume 163,586
Open 56.00
Previous Close 56.00
Day's Range 56.00 - 56.30
52-Week Range 49.75 - 63.60
Beta 0.10
RSI 43.38
Earnings Date Apr 18, 2025

About TCM Biotech International

TCM Biotech International Corp., a biotech company, engages in the research and development of drugs for the prevention and treatment of liver diseases. The company’s products include osteoarthritis treatment products, osteoporosis treatment preparations, iron supplement, urinary system treatment products, expectorants/mucolytic agents, anti-hypertensive preparations, and anti-diabetic preparations, anti-adhesion systems, pellefeel wound care systems, Philips non-invasive ventilators, and others, as well as medical devices and functional foods.... [Read more]

Sector Healthcare
Founded 1998
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4169
Full Company Profile

Financial Performance

In 2023, TCM Biotech International's revenue was 969.62 million, an increase of 20.84% compared to the previous year's 802.42 million. Earnings were 18.57 million, an increase of 1.69%.

Financial Statements

News

There is no news available yet.